305 related articles for article (PubMed ID: 30563891)
1. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
3. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
4. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
[No Abstract] [Full Text] [Related]
5.
Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
8. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
[TBL] [Abstract][Full Text] [Related]
9. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
10. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
11. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
12. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells.
Dogan Turacli I; Demirtas Korkmaz F; Candar T; Ekmekci A
J Cell Biochem; 2019 Apr; 120(4):5628-5635. PubMed ID: 30317654
[TBL] [Abstract][Full Text] [Related]
14. Characterization of
Kim S; Kim J; Jung Y; Jun Y; Jung Y; Lee HY; Keum J; Park BJ; Lee J; Kim J; Lee S; Kim J
Mol Cells; 2020 Jul; 43(7):619-631. PubMed ID: 32638704
[TBL] [Abstract][Full Text] [Related]
15. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
16. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract][Full Text] [Related]
17. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
18. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
19. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
